about
Life style prevention of cancer recurrence: the yin and the yang.Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities.Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study.Dietary glycemic load and glycemic index and risk of cerebrovascular disease in the EPICOR cohort.[Weapons of mass destruction].Exercise training improves heart rate recovery in women with breast cancer.Breast cancer survival in the US and Europe: a CONCORD high-resolution study.Community-based participatory research to improve life quality and clinical outcomes of patients with breast cancer (DianaWeb in Umbria pilot study)Postmenopausal breast cancer, androgens, and aromatase inhibitors."Open mesh" or "strictly selected population" recruitment? The experience of the randomized controlled MeMeMe trialAssociation of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study.[DianaWeb: a demonstration project to improve breast cancer prognosis through lifestyles].Adherence to WCRF/AICR cancer prevention recommendations and metabolic syndrome in breast cancer patients.Testosterone and biological characteristics of breast cancers in postmenopausal women.Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study.A pilot study with early adolescents: dealing with diet, tobacco and air pollution using practical experiences and biological markers.Effect of aerobic exercise intervention on markers of insulin resistance in breast cancer women.MiRNA-513a-5p Inhibits Progesterone Receptor Expression and Constitutes a Risk Factor For Breast Cancer: The ORDET Prospective Study.Protective Effect of Aerobic Physical Activity on Sleep Behavior in Breast Cancer Survivors.High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease.[Mediterranean diet for everyone].European Code against Cancer 4th Edition: Diet and cancer.European Code against Cancer 4th Edition: Alcohol drinking and cancer.Exercise training improves cardiopulmonary and endothelial function in women with breast cancer: findings from the Diana-5 dietary intervention study.European Code against Cancer 4th Edition: Physical activity and cancer.Recent trends of cancer mortality in Romanian adults: mortality is still increasing, although young adults do better than the middle-aged and elderly population.A randomized controlled trial of Mediterranean diet and metformin to prevent age-related diseases in people with metabolic syndrome.Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.Human IGF1 pro-forms induce breast cancer cell proliferation via the IGF1 receptor.European Code against Cancer 4th Edition: Obesity, body fatness and cancer.[Drink more milk...].Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.Dietary Glycemic Load and Index and Risk of Coronary Heart Disease in a Large Italian CohortCorrection to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patientsEuropean Code against Cancer 4th Edition: Breastfeeding and cancerLifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition studyMetabolic syndrome and breast cancer prognosisA randomized controlled trial of diet and physical activity in BRCA mutation carriers
P50
Q30354364-D3749564-45A1-4A80-BA9E-14439ED465E2Q33885363-5DA01794-73D0-4846-9146-0046B74D7A9EQ34512957-1E0E0DEB-94D2-46F8-95F1-543BD9CAAACAQ34660089-11EF5764-C769-45B8-B4AA-F550E728ABDDQ34743866-F1C36FC2-7CE3-4247-B5F6-E52A2B226696Q35172373-93925C8B-728B-49C3-A199-4D6EB5C611CCQ35907911-E9B488CE-E65E-4837-B761-A2F0BF4DBD0EQ36446450-978E2953-E715-4DF0-83E4-0C60626EF35DQ36971053-BF956AA7-015B-435F-8A0E-A5C7D296C2DBQ38097730-5A11DD10-B426-4ED9-8397-3390802653C4Q38373389-8C983000-7D2B-416C-8D1E-EF3B93E7F277Q38380655-FE6F54A6-1C43-455E-BA0C-1E70F2EB19BEQ41135467-82C0BD12-FFAD-455B-98A1-66AE8C4095E9Q41586290-641BE524-1397-4CFB-A1BD-8330753B35E3Q43258114-7E074D6A-77FB-4CEB-9035-E6FC1FFEEFD0Q44103276-06AF54B8-42A2-45C3-85A0-FEB744907DB1Q44631412-9B60B8A1-757F-43EA-9CE3-5810C68605DAQ47105751-ED49F98F-C7D8-4E20-A94C-1DB9BA6890B1Q47613525-774D6716-D982-48A9-ABD5-DA0DE8E058D4Q47617574-D3553263-615D-489C-968B-136D5B3921FEQ47850719-659CB30A-B7CA-468A-8902-AD719543C1A8Q48930446-2E0C0356-181F-463B-A9F7-05A6C9270D8EQ50099249-38181AF7-ECCB-49E6-B326-0CD26C2B30DAQ50440762-2ED347D3-7FC6-4C05-9106-AFAEEA66B50EQ51012171-977B5DD9-46EC-40FB-9371-D496A0A2A3B5Q51021393-265D5D67-EA82-4BE9-B19A-027DFF62F80AQ51027602-76675950-41EC-42D8-84E2-70A6828F9955Q51192421-180B3D85-6FD4-4182-BBAD-207222227A92Q51273550-D1562C0A-E3CE-413D-BF7D-9EDF4C96D6ADQ51747406-3691C08C-90C2-4127-8F3B-818C90102057Q53232395-61C32078-4B43-48A2-92EE-06C5822170C8Q53410935-C2621910-5C5B-4DC3-A9CF-FCE2DCA414B7Q54345919-84347276-17A4-4F02-8058-63F534B113D0Q55302514-1161C267-81EE-46C4-8E66-C6429E10A5E6Q57037598-4DD574AE-7237-45F8-892B-26EBCA00EB85Q58756742-8CDB3D43-C9EE-49A9-9D0E-46BC81EFAA4EQ59193573-6EA3E6C1-23A5-45B6-BBB5-B853A455C313Q60472154-0DAE8058-A1C7-4CD2-94DA-5B68BC6B7B38Q60627333-608C7C2E-6EB3-421A-96B7-C89F8D8416ECQ61771629-40AB9E8E-4334-48C0-ACA3-D900670189B6
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Franco Berrino
@en
Franco Berrino
@nl
type
label
Franco Berrino
@en
Franco Berrino
@nl
prefLabel
Franco Berrino
@en
Franco Berrino
@nl
P31
P496
0000-0002-4858-1866